Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Shattuck Labs Inc (STTK)

Shattuck Labs Inc (STTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 54,901
  • Shares Outstanding, K 47,740
  • Annual Sales, $ 1,660 K
  • Annual Income, $ -87,300 K
  • EBIT $ -80 M
  • EBITDA $ -77 M
  • 60-Month Beta 1.76
  • Price/Sales 29.96
  • Price/Cash Flow N/A
  • Price/Book 0.51

Options Overview Details

View History
  • Implied Volatility 309.05% ( -38.44%)
  • Historical Volatility 96.60%
  • IV Percentile 92%
  • IV Rank 41.12%
  • IV High 737.46% on 10/02/24
  • IV Low 9.84% on 08/22/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 10
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,283
  • Open Int (30-Day) 1,274

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.38
  • Number of Estimates 2
  • High Estimate -0.30
  • Low Estimate -0.46
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +7.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9400 +22.34%
on 11/22/24
1.3800 -16.67%
on 12/11/24
+0.0400 (+3.60%)
since 11/20/24
3-Month
0.9400 +22.34%
on 11/22/24
3.9500 -70.89%
on 09/30/24
-2.5900 (-69.25%)
since 09/20/24
52-Week
0.9400 +22.34%
on 11/22/24
11.7600 -90.22%
on 05/14/24
-5.3000 (-82.17%)
since 12/20/23

Most Recent Stories

More News
Shattuck Labs, Inc. to Present at Piper Sandler and Evercore Investor Conferences in December 2024

Shattuck Labs will present at two investor conferences in December 2024, focusing on its novel cancer and autoimmune disease therapeutics.Quiver AI SummaryShattuck Labs, Inc., a biotechnology company focused...

STTK : 1.1500 (+10.58%)
Shattuck Labs Announces Participation in Upcoming December Conferences

STTK : 1.1500 (+10.58%)
Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights

STTK : 1.1500 (+10.58%)
Insider Stock Research: New Fortress Energy, Marvell, and More

October has seen a flurry of insider trading activity across multiple sectors, with key executives making significant stock purchases. New Fortress Energy’s (

PLAY : 27.40 (+4.58%)
DKL : 40.49 (+1.25%)
RNAC : 19.02 (-1.30%)
COHR : 97.67 (+1.55%)
NEOG : 12.04 (+0.17%)
WOR : 40.78 (-1.07%)
NFE : 11.96 (+5.37%)
STTK : 1.1500 (+10.58%)
MRVL : 111.90 (+2.56%)
CAPR : 13.07 (+1.32%)
Shattuck Labs Reports Second Quarter 2022 Financial Results and Recent Business Highlights

– Enrollment of Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubicin in platinum-resistant ovarian cancer expected to begin in...

STTK : 1.1500 (+10.58%)
Shattuck Labs Reports First Quarter 2022 Financial Results and Recent Business Highlights

– Dose escalation ongoing in Phase 1 clinical trial of SL-172154 in platinum-resistant ovarian cancer; combination trial with liposomal doxorubicin on...

STTK : 1.1500 (+10.58%)
Shattuck Labs Presents Preclinical Data at the 2022 American Association for Cancer Research (AACR) Annual Meeting

- SL-9258 (TIGIT-Fc-LIGHT) combined with anti-PD(L)1 broadened anti-tumor activity of the checkpoint antibodies in aggressive CPI-resistant tumors - -...

STTK : 1.1500 (+10.58%)
Shattuck Labs Announces Participation in Upcoming 21st Annual Needham Virtual Healthcare Conference

AUSTIN, TX and DURHAM, NC, April 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the...

STTK : 1.1500 (+10.58%)
SHATTUCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Shattuck Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Shattuck Labs, Inc. (NASDAQ: STTK) on behalf of long-term stockholders following...

STTK : 1.1500 (+10.58%)
STTK Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Shattuck Labs, Inc. Investors of Last Few Hours to Actively Participate in the Class Action

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ: STTK) and certain...

STTK : 1.1500 (+10.58%)

Business Summary

Shattuck Labs Inc. is a clinical-stage biotechnology company. It engages in development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. The company's wholly owned program includes SL-172154. It operates principally in Durham, North...

See More

Key Turning Points

3rd Resistance Point 1.3400
2nd Resistance Point 1.2500
1st Resistance Point 1.2000
Last Price 1.1500
1st Support Level 1.0600
2nd Support Level 0.9700
3rd Support Level 0.9200

See More

52-Week High 11.7600
Fibonacci 61.8% 7.6268
Fibonacci 50% 6.3500
Fibonacci 38.2% 5.0732
Last Price 1.1500
52-Week Low 0.9400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar